Preventing Influenza A Virus Infection by Mixed Inhibition of Neuraminidase and Hemagglutinin by Divalent Inhibitors-Reference-Cited by-同舟云学术

Preventing Influenza A Virus Infection by Mixed Inhibition of Neuraminidase and Hemagglutinin by Divalent Inhibitors

Published:2022-05-12 Issue:10 Volume:65 Page:7312-7323
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wei Xuan¹,Du Wenjuan²,Duca Margherita¹,Yu Guangyun¹,de Vries Erik²,de Haan Cornelis A. M.²,Pieters Roland J.¹^ORCID

Affiliation:

1. Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, Utrecht NL-3508 TB, The Netherlands

2. Section Virology, Division Infectious Diseases and Immunology, Faculty Veterinary Medicine, Utrecht University, Utrecht NL-3508 TB, The Netherlands

Funder

China Scholarship Council

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00319

Reference45 articles.

1. Influenza: old and new threats

2. Influenza A virus transmission via respiratory aerosols or droplets as it relates to pandemic potential

3. Kinetic analysis of the influenza A virus HA/NA balance reveals contribution of NA to virus-receptor binding and NA-dependent rolling on receptor-containing surfaces

4. Influenza A Virus Hemagglutinin–Neuraminidase–Receptor Balance: Preserving Virus Motility

5. Role of receptor binding specificity in influenza A virus transmission and pathogenesis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biolayer interferometry and its applications in drug discovery and development;TrAC Trends in Analytical Chemistry;2024-07

2. Modular Biomimetic Strategy Enables Discovery and SAR Exploration of Oxime Macrocycles as Influenza A Virus (H1N1) Inhibitors;Journal of Medicinal Chemistry;2024-05-13

3. Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges;Drug Resistance Updates;2024-03